Read more

March 16, 2022
1 min read
Save

Stromal vascular fraction yielded acceptable midterm outcomes for patients with knee OA

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Autologous stromal vascular fraction treatment yielded “acceptable clinical states” in most patients with knee osteoarthritis at 5 years, according to published results.

In a single center, randomized controlled trial, researchers analyzed clinical outcomes of 56 patients who received stromal vascular fraction (SVF) treatment and a control group of 70 patients who received a hyaluronic acid (HA) injection for OA with a minimum 5 years of follow-up. Outcome measures, including VAS pain scores and WOMAC scores, were assessed at 1-, 2-, 3- and 5-year intervals. Researchers defined the endpoint as surgery related to knee OA or a clinical score exceeding the patient-acceptable symptom state.

OT0322Zhang_14_Graphic_01
VAS pain scores improved from 3.96 to 2.86 in the SVF group, while VAS scores worsened from 3.55 to 3.95 in the HA group. Data were derived from Zhang S, et al. Stem Cell Res Ther. 2022;doi:10.1186/s13287-022-02788-1.

At 5-year follow-up, the SVF group had a response to treatment rate of 62.5% (n = 35) and the HA group had a response to treatment rate of 20% (n = 14). Researchers also noted the SVF group had an average responsive time to treatment of 61.52 months, while the HA group had an average response time to treatment of 30.37 months.

From pre-treatment to 5 years, VAS pain scores improved from 3.96 to 2.86 in the SVF group, while VAS scores worsened from 3.55 to 3.95 in the HA group. Similarly, WOMAC scores improved from 33.24 to 27.04 in the SVF group from pre-treatment to 5 years, while WOMAC scores worsened from 28.44 to 36.05 in the HA group. The HA group saw a greater reduction in cartilage volume compared with the SVF group. Additionally, a hazard model showed bone marrow lesion severity and BMI were independent predictors of prognosis.

“The most important finding of this study is that acceptable clinical state was present for approximately 60% of patients after SVF treatment,” the researchers wrote in the study. “Targeting SVF injections to specific lesion sites and tracking the localization of SVF cells under MRI is a direction for future research,” they added.